NDA 022462 · Piramal Critical
Gablofen
Baclofen · Intrathecal · gamma-Aminobutyric Acid-ergic Agonist
Last checked: Nov 20, 2026Latest source record: May 31, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Nov 19, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
123
30 Phase 3, 6 recruiting
FAERS reports
3,114
1,575 serious, 121 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
BOXED WARNING WARNING: DO NOT DISCONTINUE ABRUPTLY Abrupt discontinuation of intrathecal baclofen, regardless of the cause, has resulted in sequelae that include high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, that in rare cases has advanced to rhabdomyolysis, multiple organ-system failure and death. Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms. Patients and caregivers should be advised of the importance of keeping scheduled refill visits and should be educated on the early symptoms of baclofen withdrawal. Special attention should be given to patients at apparent risk (e.g., spinal cord injuries at T-6 or above, communication difficulties, history of withdrawal symptoms from oral or intrathecal...
What it is approved for
From the label in effect May 7, 2026.
GABLOFEN is indicated for use in the management of severe spasticity in adult and pediatric patients age 4 years and above. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of GABLOFEN via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. GABLOFEN is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only with the Medtronic SynchroMed ® Programmable Pump or other pumps labeled for intrathecal administration of GABLOFEN [see Clinical Studies (14)] . Prior to implantation of a device for chronic intrathecal infusion of GABLOFEN, patients must show a response to GABLOFEN in a screening trial [see Dosage and Administration (2.2)] . GABLOFEN is a gamma-aminobutyric acid (GABA) ergic agonist indicated for use in the management of severe spasticity of cerebral or spinal origin in adult and pediatric patients age 4 years and above. ( 1 ) GABLOFEN should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable central nervous system side effects at effective doses. ( 1 ) Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. ( 1 ) Spasticity due to traumatic brain injury: wait at least one year after injury before considering GABLOFEN therapy. (...
Mechanism: The precise mechanism of action of baclofen as a muscle relaxant and antispasticity agent is not fully understood. Baclofen inhibits both monosynaptic and polysynaptic reflexes at the spinal level, possibly by decreasing excitatory neurotransmitter release from primary afferent terminals, although actions at supraspinal sites may also occur and contribute to its clinical effect. Baclofen is a structural analog of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), and may exert its effects by stimulation of the GABAB receptor subtype. Baclofen when introduced directly into the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 19, 2010 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewSummary Review
4 products under this application
- GABLOFEN · BACLOFEN 1MG/ML · INJECTABLE, INTRATHECAL · Prescription · TE AP
- GABLOFEN · BACLOFEN 0.5MG/ML · INJECTABLE, INTRATHECAL · Prescription · TE AP
- GABLOFEN · BACLOFEN 2MG/ML · INJECTABLE, INTRATHECAL · Prescription · TE AP
- GABLOFEN · BACLOFEN 0.05MG/ML · INJECTABLE, INTRATHECAL · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Baclofen" as an intervention, any sponsor and status, largest first.
- The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes ZosterPivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07378046 · 750 participants (planned) · Start Dec 15, 2025 · Primary completion Sep 30, 2027
Drug: Baclofen combined conventional therapy; Conventional therapy · For: Herpes Zoster; Pain
Sites: Beijing, China
- An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain ServicePivotal-lookingNot yet recruiting
University of California, San FranciscoAcademic, hospital or other
NCT07296770 · 474 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 1, 2028
Drug: Pharmacologic Pain Management · For: Postsurgical Pain Management; Postsurgical Pain, Chronic; Opioid Use After Surgery
Sites: San Francisco, California
- A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump InhibitorsPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT01265550 · 366 participants · Start Aug 13, 2012 · Primary completion Dec 30, 2016
Drug: baclofen; Desipramine · For: GERD
Sites: Birmingham, Alabama; Tucson, Arizona; Loma Linda, California · 15 sites in all
- Efficacy Study of Arbaclofen to Treat Spasticity in Multiple SclerosisPivotal-lookingCompleted
RVL Pharmaceuticals, Inc.Industry
NCT01743651 · 353 participants · Start Nov 2012 · Primary completion Apr 2014
Drug: arbaclofen; baclofen and 1 more · For: Spasticity; Multiple Sclerosis
Sites: Cullman, Alabama; Long Beach, California; Aurora, Colorado · 48 sites in all
- Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A PatientsPivotal-lookingStatus unknown
Pharnext S.C.A.Academic, hospital or other
NCT04762758 · 350 participants (planned) · Start Mar 30, 2021 · Primary completion Apr 19, 2024
Drug: (RS)-baclofen, naltrexone hydrochloride and D-sorbitol; Placebo · For: Charcot-Marie-Tooth Disease
Sites: Los Angeles, California; Sacramento, California; New Britain, Connecticut · 50 sites in all
- A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MSPivotal-lookingCompleted
RVL Pharmaceuticals, Inc.Industry
NCT03319732 · 323 participants · Start Apr 3, 2018 · Primary completion Jan 27, 2020
Drug: Arbaclofen · For: Multiple Sclerosis; Spasticity, Muscle
Sites: Fresno, California
- Baclofen for the Treatment of Alcohol DrinkersPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01604330 · 323 participants · Start May 29, 2012 · Primary completion Sep 2014
Drug: Baclofen; Placebo · For: Alcoholism
Sites: Paris, France
- Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back PainPivotal-lookingCompleted
Montefiore Medical CenterAcademic, hospital or other
NCT03068897 · 320 participants · Start May 3, 2017 · Primary completion Jul 11, 2018
Drug: Metaxalone; Tizanidine and 2 more · For: Low Back Pain
Sites: The Bronx, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- muscle spasticity771
- withdrawal syndrome421
- device issue376
- drug ineffective294
- drug withdrawal syndrome272
- overdose172
- implant site infection166
- infection164
- hypertonia158
- pruritus157
- device failure154
- device malfunction151
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 3 |
| 2012 | 15 |
| 2013 | 333 |
| 2014 | 243 |
| 2015 | 318 |
| 2016 | 145 |
| 2017 | 139 |
| 2018 | 684 |
| 2019 | 42 |
| 2020 | 247 |
| 2021 | 203 |
| 2022 | 269 |
| 2023 | 170 |
| 2024 | 120 |
| 2025 | 121 |
| 2026 | 62 |
Recalls
1 FDA enforcement reports for this application.
Jul 8, 2019 · Class II · Terminated
Failed Impurities/Degradation Specification -This recall is being initiated as a precaution due to the presence of an unknown impurity observed during shelf life of the product.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Gablofen (Baclofen)
2024 spending
$131K
Beneficiaries
34
108 claims
Per beneficiary
$3,858
$42.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $109,598 |
| 2021 | $82,815 |
| 2022 | $90,380 |
| 2023 | $108,008 |
| 2024 | $131,171 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dystonia.
Snaith A, Wade D · BMJ Clin Evid 2014 · Systematic Review
- Pharmacologic Interventions for Intractable and Persistent Hiccups: A Systematic Review.
Polito NB, Fellows SE · J Emerg Med 2017 · Systematic Review
- Cluster headache.
Matharu M, Silver N · BMJ Clin Evid 2008 · Systematic Review
- Multiple sclerosis.
Nicholas R, Rashid W · BMJ Clin Evid 2012 · Systematic Review
- Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.
Bahji A, Bach P, Danilewitz M, et al. · J Addict Med 2022 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Trigeminal neuralgia.
Zakrzewska JM, Linskey ME · BMJ Clin Evid 2009 · Systematic Review
Sponsor: Piramal Critical
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.